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Abstract
Background: The consumption of EPA (Eicosapentaenoic
acid), and DHA (docosahexaenoic acid), from fish oil, in the long
run, has been observed to have a positive impact on patients with
coronary heart disease. Fish oil products, with so much EPA and
DHA content are available, and have very variable prices.
Therefore, as a therapy to be used for long-term treatment, the cost
factor is to be considered.
Design and methods: This study analyzed the content of EPA
and DHA, using GC-MS. The sample to be analyzed was the fish
oil that has the lowest price (Product A1), and that of the highest
(Product A2). Furthermore, the macroscopic analysis was per-
formed, by observing the physical form including organoleptic
and qualitative tests, by reading the fragments identified by EPA
and DHA.
Results: Clinical trials were conducted on patients (about 46
people), with risk factors and dyslipidemia. Product A1 showed
EPA at tR= 15.574 min (relative%= 88.49%, similarity= 95%), and
DHA at tR= 21.714 min (relative%= 88.92%, similarity= 93%).
Product A2 showed EPA at tR= 28.719 min (relative%= 22.58%,
similarity= 89%), and DHA at tR= 32.327 min (relative%= 22.87%,
similarity= 90%), which meant that both had EPA and DHA con-
tents, in accordance with their labels. Both products were con-
firmed to reduce total cholesterol in 4weeks (p=0.000, p= 0.000),
with no significant difference in their effectiveness (p=0.652).
Conclusion: The results showed that both the A1 and A2 prod-
ucts, had the EPA and DHA contents in accordance with their
respective labels. However, with the A2 product having a percent-
age relatively higher than that of the A1 brand, both are equally
very effective.
Introduction
World Health Organization described cardiovascular disease
as the top leading cause of death in the world. In 2005, an estimat-
ed number of 17 million people died of cardiovascular disease,
representing 30% of the total global mortality. About 80% of these
deaths occurred in low- and middle-income countries.1 In
Indonesia, this condition is included in the top 10 non-communi-
cable diseases, experienced by many people. Furthermore, cardio-
vascular disease often encountered by adult, is coronary heart ill-
ness and failure.2 Deaths caused by this condition, especially coro-
nary heart disease (CHD) and stroke, keep on increasing, and pre-
dicted to reach 23.3 million mortality by 2030.3
The biggest risk factors for CHD are, obesity and diabetes,
with overweight adolescents, which increase the number of obese,
by an additional 5%-15% in 2035, resulting to 100,000 new
cases.4 The heart obtains lipids from circulating non-esterified
fatty acids (FFAs), and esterified FAs, bound to lipoprotein. The
abnormal regulation of lipid uptake, or its intracellular metabo-
lism, play an important role in heart diseases.5 This supports the
theory that, there is a relationship between cholesterol level
(LDL), and the risk of cardiovascular disease (CVD).6
Also, blood cholesterol is related to the amount of fat, in the
composition of daily food (diet). Cholesterol-lowering diets
include delicacies that are low in fat, replacing food composition
with those containing unsaturated fats, or rich in omega-3.7,8
Omega-3 polyunsaturated fatty acids (n-3 PUFAs), consists of
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)
contents. It is widely contained in fish, possessing protective
effects, against cardiovascular disease and hyperlipidemia.9,10
DHA and EPA are important food nutrients for human health,
which are defined as essential fatty acids, because they are not
synthesized by the body, and are often obtained from the
diet.11 These nutrients play an important role in the human body,
by reducing bad cholesterol, in a bid to prevent CHD,12,13 through
pleiotropic effects on cell function, which does affect blood lipids,
inflammation, with endothelial cell and cardiomyocyte roles.14
EPA and DHA consumption in the long run, has been observed
to have a positive effect on patients with CHD, to reduce the risk
of sudden death.15 Intake of fish oil containing EPA and DHA
1g/day, has been widely recommended for CHD patients.
However, intake in excess of 3 g/day is also not recommended,
because it can reduce immune system function, as it lowers body
inflammatory responses, and increases bleeding time due to high
dosage.16
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Significance for public health
Omega-3 consists of EPA and DPA, that provides significant benefits in lowering total cholesterol, which also, reduces the risk of cardiovascular disease. The
omega-3 products in the market have relative percentage variability that affects the purification formulas of EPA and DHA, which often cause very large price
variations. Furthermore, it is necessary to identify, whether the price difference also affects its effectiveness.









Fish oil products that have so much EPA and DHA contents,
are available, and have very variable prices. Furthermore, as a ther-
apy to be used for long-term treatment, the cost factor is to be con-
sidered, because it is related to compliance,17 economic burden,18
and quality of life.19 Therefore, in this study, quality control needs
to be conducted, in the form of a qualitative test, to see the suitabil-
ity of the EPA and DHA contents on the label. 
The profiles of the chemical compounds are to be identified by
using GC-MS chromatography method. The GC-MS method, used
in fish oil analysis for the determination of EPA and DHA, has
been confirmed to be effective and accurate.20,21 Also, EPA and
DHA are to be analyzed, by using High Performance Liquid
Chromatography (HPLC), and Liquid Chromatography Mass
Spectrometry (LC-MS), with the HPLC not as sensitive enough
like the GC-MS, while requiring very high costs when using LC-
MS.20 Also, clinical trials are to be conducted, in comparing the
two products, to observe the effects of EPA and DHA, in the reduc-
tion of blood cholesterol levels (LDL, total cholesterol, and
triglycerides). Therefore, the aim of this study is to determine the
composition of EPA and DHA in fish oil products, for cardiovas-




This study analyzed the contents of EPA and DHA from two
fish oil products, for cardiovascular disease therapy in Indonesia,
through qualitative analysis, using GC-MS, in April to December
2017. The sample to be investigated, was the fish oil that had the
lowest price (Product A1, Batch Number, 604683 and Exp.Date,
January 2019), and the highest rate (Product A2, Batch Number,
OCT16AO1 and Exp.Date, February 2019). The study was con-
ducted in a quantitative analysis chemistry laboratory, at the
Faculty of Pharmacy, University of Surabaya, Indonesia.
Chemicals and equipment
The chemicals used in this study included n-hexane p.a, satu-
rated sodium chloride p.a, potassium hydroxide p.a, methanol p.a,
boron-trifluoride (BF3), and distilled water. The equipment used in
this study included beaker glass, measuring cup, closed test tube, 5
ml/cc injection syringe, vials, membrane filter, millipore holder,
Shimadzu QP-2010 SE brand GC-MS, Japan-using capillary col-
umn RTX-5SM (60 m x 0.25 mm, layer thickness 0.25 µm), with
minimum column temperature of 330°C-350°C, used for sample
separation. For temperature programming, the oven was main-
tained at 80°C for one min, increased at intervals of 10°C/min to
250°C, then reduced to 8°C/min to 280°C, and balanced for 5 min.
Split injection was performed at a ratio of 1:200, as an helium car-
rier gas, with 1 µl injection volume of 0.73 ml/min was used. The
mass spectrum, was operated in electron impact mode (EI).
Furthermore, other parameters included, pressure 100 Kpa, injec-
tion temperature 250°C, ion source EI 200°C, interface tempera-
ture 220°C, electron energy 70 eV, delay solvent 5 min. For the
qualitative analysis the full scan mode used for variously was 40-
400m/z (Figure 1).
Qualitative test
Qualitative tests carried out included, organoleptic observation
(visual conditions based on shape, smell, taste, and color), and
sample making. A 3 ml fish oil in soft capsules, was obtained, and
placed into a centrifuge tube, with 3 ml of potassium hydroxide
methanol (0.5 M) solution added to it. The solution was mixed
together vigorously, until it became homogeneous, then heated in
a 60°C water bath, hydrolyzed with nitrogen gas flow, while being
stirred three times, for 20 min. Furthermore, 3 ml of BF3 was
added, after which the solution was cooled. The solution was heat-
ed at 60°C of water bath, and hydrolyzed again with nitrogen gas,
for 5 min. Saturated sodium chloride solution of 2 ml, and 2 ml n-
hexane were added, mixed vigorously and centrifuged at 4000
rpm, for 10 min. Supernatant was also obtained for use, as a sam-
ple solution. An aliquot of 1 µl supernatant, was then injected for
GC-MS analysis (Figure 2).
Clinical trials
The clinical trials in humans used the randomized controlled
trial (RCT) method. The research subjects were adults aged >18-
year-old, and dyslipidemic patients having ≥1 of CVD risk factors,
with CHD uncertainty. The assessment of CVD risk factors in the
next 10 years are conducted, using the Framingham risk score.22
This includes body mass index (BMI), blood pressure, smokers,
physical activity, and increased blood sugar.23-25 The criteria for
the study subjects were, no history of kidney and heart disease. The
research subjects were divided into two groups namely, those that
use A1 and A2 products routinely, everyday. Each group watched
for 4 weeks, and consisted of 23 people, with a purposive sampling
method. Further test was carried out for total cholesterol (mg/dl),
using Accutrend® GCT (Figure 3). 
The sample size used in this study was 23 people, taking into
account the value of Z=1.96 and p=0.015, which is the proportion
for certain properties, estimated from Indonesian Heart
Association (2017).26
Results and Discussions
Identification of omega 3 in fish oil
The organoleptic observations of product A1 and A2 included,
shape, color, odor, and taste. The results showed that, both prod-
ucts have the same form (oil), color (clear yellow), smell (fishy),  
and taste (like fish). The results of the study by GC-MS, obtained
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Figure 1. EPA and DHA test scheme on fish oil with GCMS.










two chromatograms and mass spectra, which were derived as prod-
ucts from the analysis. The identification of fish oil using Gas
Chromatography-Mass Spectroscopy (GC-MS), showed 49 peaks
on the chromatogram profile shown in Figure 4, with the highest
observed at 28 and 32. The mass spectrum of the compound at
peak 28, with tR= 28.719 min (22.58%), showed Ethyl 5,8,11,14,17
Eicosapentaenoate (Figure 5a). Based on data from the
NIST08.LIB library, Ethyl 5,8,11,14,17 Eicosapentaenoate has the
molecular formula C21H3202, with a molecular weight of 316, and a
basic peak at m/z 79. The structure shown is clearly the same as
that of the EPA in Figure 5a, with 89% similarity.
The mass spectrum of the compound at peak 32 with tR=
32.327min (22.88%), showed 4,7,10,13,16,19 Docosahexaenoic
acid methyl ester, as shown in Figure 5b. Based on data from the
NIST08.LIB library, 4,7,10,13,16,19 Docosahexaenoic acid
methyl ester, has a molecular formula C23H3402, with a molecular
weight of 342, and a base peak at m/z 79. The structure that shown
is clearly observed in the appendix, equal to that of the DHA, as
shown in Figure 5b, with 90% similarity (Figure 5b).
Identification of fish oil using Gas Chromatography-Mass
Spectroscopy (GC-MS), showed 50 peaks on the chromatogram
profile shown in Figure 6, with the highest observed at 4 and 22,
respectively (Figure 6). The mass spectrum of the compound, at
peak 4 with tR=15.574 min (88.49%), showed Ethyl 5,8,11,14,17
Eicosapentaenoate (Figure 7a). Based on data from the
NIST08.LIB library, Ethyl 5,8,11,14,17 Eicosapentaenoate has the
molecular formula C21H3202, with a molecular weight of 316, and a
basic peak at m/z 79. The structure shown is more clearly the same
as that of the EPA in Figure 7a, with 95% similarity.
The mass spectrum of the compound at peak 32 with tR=
32.327mins (22.88%), showed 4,7,10,13,16,19 Docosahexaenoic
acid methyl ester, as shown in Figure 5b. Based on data from the
NIST08.LIB library, 4,7,10,13,16,19 Docosahexaenoic acid
methyl ester, has a molecular formula C23H3402, with a molecular
weight of 342, and a base peak at m/z 79. The structure shown is
more clearly observed in appendix, equal to that of the DHA in
Figure 5b, with 93% similarity (Figure 7b).
Data analysis
The calculations to determine the level of compounds con-
tained in a sample, is conducted, using the equation, %relative=
(area÷area total) x100% (Table 1). The product A1, with the lowest
price after being identified using GC-MS, showed EPA at tR=
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Figure 2. Work scheme preparation of fish oil samples.
Figure 4. Chromatography profile of Product A1.
Figure 5. a) EPA peak mass spectrum highest area. b) DHA mass
spectrum peaks the highest area of sample A1.
Figure 3. Cholesterol measurement tool.
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28.719mins, with relative%= 22.58%, having a similarity of 89%,
and DHA at tR= 32,327mins, with relative%= 22.87%, possessing a
90% similarity, which means that both contents are compatible
with the label (Figure 8a). Furthermore, product A2, with the high-
est price, showed EPA at tR=15.574 min, with relative%= 88.49%,
having a 95% similarity, and DHA at tR= 21.714 min, with rela-
tive% = 88.92%, possessing a 93% similarity, which means that
both contents are also compatible with the label (Figure 8b).
Product effectiveness data
Based on the characteristics shown by the respondents, major-
ity were women, with an average age, early adult, and are students.
The average pre-post total cholesterol in both product group, is
above the normal average value (<200 mg/dl) (Table 2). Based on
Table 3, both product groups showed changes in pre (p=0.000),
and post (p=0.000), meaning they are equally effective in reducing
total cholesterol in the blood. However, the two products showed
no difference in their effectiveness, when reducing total choles-
terol (p=0.652).
The study showed that 3 ml of fish oil in soft capsule, was
inserted into a centrifuge tube. The sample mixed with 3 ml of
KOH, was useful for hydrolyzing into esters, or called derivatiza-
tion. Both EPA and DHA which were then heated in 60°C water,
completely hydrolyzed and flowed with nitrogen gas, to avoid
being oxidized, and stirred three times for 20 min. The fish oil was
known to have a high vapor point, because the constituent sub-
stance was triacylglycerol. Therefore, before being analyzed by
GC-MS, the methyl ester form was changed, using methanol and
Boron trifluoride (BF3) as a catalyst. This form of fatty acid methyl
ester, was then injected into the GC-MS device. BF3 was added to
the sample, and the solution was cooled.
BF3 bind well to atoms with high electronegativity, to form
complexes. The solution was heated over a 60°C water bath for
5mins. Saturated sodium chloride solution of 2 ml and 2 ml n-
hexane were added together, mixed vigorously, and centrifuged
(4000 rpm) for 10 min. N-hexane is a solvent that was used,
because of its low boiling point, lightness  in removing the oil con-
tained, and volatility in making extraction easy. Saturated NaCl
was added to reach salting in the centrifuge, with n-hexane dis-
solved phase injected into GC-MS, as much as 1 µl.
The results of the test with GC-MS, obtained two chro-
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Figure 6. Chromatography profile of Product A2.
Figure 7. a) EPA peak mass spectrum highest area. b) DHA mass
spectrum peaks the highest area of sample A2.
Figure 8. a) Label of Product A1 (1200 mg: 360 EPA and 240
DHA). b) Label of Product A2 (1000 mg: 180 EPA and 120
DHA).
Table 1. Comparison of EPA and DHA in Product A1 and A2. 
Product A1                                                            Product A2
          Components                                                  Area     % Relative           Components                                                         Area  % Relative
Ethyl 5,8,11,14,17 Eicosapentaenoate                                 4073005037      22.58%                   Ethyl 5,8,11,14,17 Icosapentaenoate                                449971252    88.49%
4,7,10,13,16,19 Docosahexaenoic acid, methyl ester       4124358876      22.87%                   4,7,10,13,16,19 Docosahexaenoic acid, methyl ester   451560536    88.92%
Table 2. Characteristics of respondents.
                                                                                                         Groups
                                                                                                                                  Product A1                                 Product A2
                                                                                                                                    (N=23)                                     (N=23)
Gender                                              Male                                                                                                                     3      (13.04%)                                                     4     (17.39%)
                                                           Female                                                                                                               20     (86.96%)                                                    19    (82.61%)
Age (years)                                      Early adulthood (26-35)                                                                                 20     (86.96%)                                                    21    (91.30%)
                                                           Late adulthood (36-45)                                                                                   3      (13.04%)                                                     2      (8.70%)
Occupation                                      College student                                                                                                18     (78.26%)                                                    18    (78.26%)
                                                           Employee                                                                                                            5      (21.74%)                                                     5     (21.74%)
Average of total Cholesterol       Baseline (pre)                                                                                         245.1                                                        241.7









matograms, for gas chromatography (GC), and mass spectra, for
that of mass spectroscopy (MS) analysis, functioning as x-axis
(intensity) and y-axis (mass per charge (m/z)), respectively. The
results showed that, both the A1 and A2 products had the EPA and
DHA contents, in accordance with their respective labels.
Furthermore, the A2 product has a relatively higher percentage
than the A1 brand, which then shows that the compound content,
contained in the A2 sample is very high. Therefore, it can be con-
cluded that, there is a relationship between price and both product
contents, as observed from the relative percentage. Product A1
(with the lowest price), has relatively lower percentage, compared
to brand A2 (with the highest price), which has relatively higher
grade, although the dosage stated on the label of A1, is higher than
that of A2. The result in Table 3, showed that the two therapy
groups were equally effective at lowering total cholesterol, and
there was no significant difference in effectiveness. Also, gender
did not affect the risk of dyslipidemia.27 Furthermore, race factors
affected the treatment of dyslipidemia more. Also, the result of the
study explained that hyperlipidemia is more aggressively treated
and controlled in white men, than in white women. However, black
women are at the highest risk of CHD, than others.28 The age and
educational level also affects dyslipidemia treatments, with the
most at risk in the 50-59 years-old group. Dyslipidemia, is mostly
served by patients with low levels of education.29
The sytematic review by Nejad and Bikdeli,30 in an early study,
showed that supplementation with 1g of omega-3 per day, signifi-
cantly reduced mortality. A double-blind randomized in France,
showed that, in 633 patients taking 600mg of omega-3 daily, for an
average of 4.7 years, did not find significant decrease in major car-
diovascular events. The same is the case with other studies in
Netherlands, with randomized double-blind placebo-controlled trials,
showing that, in 1,192 CVD patients using supplements with an aver-
age of 226 mg EPA, and 150 mg DHA per day, did not show signif-
icant decrease in major cardiovascular events. While another study in
Germany, found no additional benefit from 1g of omega-3 per day,
for one year, against sudden cardiac death, and other cardiovascular
events. This study had limitations, which is, not being able to know
how significant the relative percentage difference is. Therefore, it is
recommended for further research to determine the levels of product
contents in a fish oil product, with a comparison of pure EPA and
DHA. Furthermore, research is also needed to observe cost-effective
events between the cost of drugs, with effectiveness in reducing cho-
lesterol levels. Also, factors of race and occupation/education, related
to health affects the risk of dyslipidemia, and adherence to medica-
tion. Further research is also needed, to compare natural resources
with supplements. Omega-3 sources are more recommended in the
form of food intake from fish, rather than in the form of
supplements.31 Also, to lower cholesterol in the blood, omega-3s
reduces blood pressure,32 with further research needed, to observe
changes in the system. Also, future clinical trials need to pay attention
to genetic related factors including, apoliprotein AI (apoA-I), ATP-
binding cassette transporter A1 (ABCA1), ABCG1, apoE, scavenger
receptor class B type I (SR-BI), cholesteryl ester transfer protein
(CETP), low-density lipoprotein receptor (LDLr), cholesterol 7
alpha-hydroxylase (CYP7A1), and ABCG5/G8.33
Conclusions
The results showed that both the A1 and A2 products had the
EPA and DHA contents in accordance with their respective labels.
Also, with the A2 product having a relatively higher percentage
than the A1 brand, it is shown that the compound content in the A2
sample, is high. Therefore, it can be concluded that, there is a rela-
tionship between price with, EPA and DHA content, as observed
from relative percentage. Product A1 (with the lowest price), has
relatively lower percentage, compared to brand A2 (with the high-
est price), with relatively higher grade. Therefore, both products
are confirmed to reduce total cholesterol in 4 weeks, with no sig-
nificant difference in their effectiveness.
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Table 3. Measurement of total cholesterol profile
Groups                                              Changes in the value of total cholestero                                                                      p-value p-value
                                                  Increase                   Fixed                    Decrease                     (pre-post)                 (post A1 vs Post A2)
Product A1 (n:23)                                          1                                       4                                      18                                          0.000                                               0.652
Product A2 (n:23)                                          0                                       4                                      19                                          0.000                                                   
p<0.05 means that there are significant differences.
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ABSTRACT
Background: The consumption of EPA (Eicosapentaenoic acid), and DHA (docosahexaenoic acid), from fish
oil, in the long run, has been observed to have a positive impact on patients with coronary heart disease.
Fish oil products, with so much EPA and DHA content are available, and have very variable prices.
Therefore, as a therapy to be used for long-term treatment, the cost factor is to be considered.
Design and methods: This study analyzed the content of EPA and DHA, using GC-MS. The sample to be
analyzed was the fish oil that has the lowest price (Product A1), and that of the highest (Product A2).
Furthermore, the macroscopic analysis was performed, by observing the physical form including
organoleptic and qualitative tests, by reading the fragments identified by EPA and DHA.
Results: Clinical trials were conducted on patients (about 46 people), with risk factors and dyslipidemia.
Product A1 showed EPA at t 15.574 min (relative%= 88.49%, similarity= 95%), and DHA at t 21.714 min
(relative%= 88.92%, similarity= 93%). Product A2 showed EPA at t 28.719 min (relative%= 22.58%,
similarity= 89%), and DHA at t 32.327 min (relative%= 22.87%, similarity= 90%), which meant that both
had EPA and DHA contents, in accordance with their labels. Both products were confirmed to reduce total
cholesterol in 4weeks (p=0.000, p= 0.000), with no significant di erence in their e ectiveness (p=0.652).
Conclusion: The results showed that both the A1 and A2 products, had the EPA and DHA contents in
accordance with their respective labels. However, with the A2 product having a percentage relatively higher
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